Drug survival of biologic therapy in a large, disease‐based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)-Reference-Cited by-同舟云学术

Drug survival of biologic therapy in a large, disease‐based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Published:2016-03-30 Issue:7 Volume:30 Page:1148-1158
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Menter A.¹,Papp K.A.²,Gooderham M.³,Pariser D.M.⁴,Augustin M.⁵,Kerdel F.A.⁶,Fakharzadeh S.⁷,Goyal K.⁷,Calabro S.⁷,Langholff W.⁸,Chavers S.⁹,Naessens D.¹⁰,Sermon J.¹⁰,Krueger G.G.¹¹

Affiliation:

1. Baylor University Medical Center Dallas TX USA

2. K Papp Clinical Research and Probity Medical Research, Inc. Waterloo Ontario Canada

3. SKIN Centre for Dermatology and Probity Medical Research Peterborough Ontario Canada

4. Eastern Virginia Medical School and Virginia Clinical Research Norfolk VA USA

5. University Medical Center Hamburg‐Eppendorf Hamburg Germany

6. Florida Academic Dermatology Centers Miami FL USA

7. Janssen Scientific Affairs LLC Horsham PA USA

8. Janssen Research & Development LLC Horsham PA USA

9. Janssen Research & Development LLC Titusville NJ USA

10. Janssen‐Cilag NV Beerse Belgium

11. University of Utah School of Medicine Salt Lake City UT USA

Funder

Janssen Scientific Affairs, LLC, Horsham, PA, USA.

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.13611

Reference30 articles.

1. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis

2. Antidrug antibodies in psoriasis: a systematic review

3. A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs. conventional systemic therapies;Levin AA;J Drugs Dermatol,2014

4. Drug survival rates in patients with psoriasis after treatment with biologics

5. ‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the Bio CAPTURE network

Cited by 224 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improving systemic therapy selection for inflammatory skin diseases: A clinical need survey;JAAD International;2024-09

2. A Comprehensive Review of the Factors Affecting the Redefinition of Therapeutic Use in Metropolitan Cities during the Emerging and Re-emerging Pandemics;Romanian Journal of Military Medicine;2024-09-01

3. Investigating EGFR, BRAF, and RAS Mutations in Oral and Cutaneous Squamous Cell Neoplasms: A Preliminary Report on Romanian Patients;Romanian Journal of Military Medicine;2024-09-01

4. Persistence of advanced systemic pharmacological treatment of moderate‐to‐severe psoriasis among bio‐naïve patients—A retrospective register‐based cohort study in Finland and Sweden;Journal of the European Academy of Dermatology and Venereology;2024-08-02

5. Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis;Drugs & Aging;2024-08